Status:
RECRUITING
Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study
Lead Sponsor:
Bart Rijnders
Conditions:
Invasive Aspergillosis
Eligibility:
All Genders
18+ years
Brief Summary
Invasive aspergillosis (IA) is the most common mould infection in immunocompromised patients with haematological disease. Voriconazole, a triazole, improves overall survival of patients with an IA and...
Eligibility Criteria
Inclusion
- 18 years or older.
- Lung CT shows lesions that fulfil the EORTC/MSG radiological criteria of possible invasive fungal infection.
- A bronchoalveolar lavage is planned or has been performed \<48hrs earlier
Exclusion
- \- Patients unable or unwilling to provide consent
Key Trial Info
Start Date :
July 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06069505
Start Date
July 1 2017
End Date
December 31 2030
Last Update
May 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus Medical Center (EMC)
Rotterdam, South Holland, Netherlands, 3000 CA